К. А. Саранцева
Pirogov Russian National Research Medical University · 60 works · 60 citations · h-index 4
Top works
- Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report
- Immunotherapy for non-small cell lung cancer treatment
- Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
- Иммунология: формирование иммунного ответа как ведущего фактора противоопухолевой защиты
- Pseudoprogression in patients on immunotherapy
- IMMUNE-MEDIATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS THERAPY
- A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer
- Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
- First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
- RESULTS OF NIVOLUMAB USE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE OF THE N.N. BLOKHIN CANCER RESEARCH CENTER
- KRAS-mutated non-small cell lung cancer: new therapy strategies
- ПОИСК ЛАБОРАТОРНЫХ ПРЕДИКТОРОВ РАЗВИТИЯ ЭНДОКРИННЫХ ИММУНООПОСРЕДОВАННЫХ НЕЖЕЛАТЕЛЬНЫХ ЯВЛЕНИЙ ДО НАЧАЛА ПРОВЕДЕНИЯ ИММУНОТЕРАПИИ ИНГИБИТОРАМИ КОНТРОЛЬНЫХ ТОЧЕК ИММУННОГО ОТВЕТА
- A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma
- Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.
- Relationship between molecular genetic and clinical and morphological parameters in patients with stage I–IIIA non-small cell lung cancer
- Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy
- Genomic characteristics of Russian patients with non-small cell lung cancer: Results of next-generation sequencing testing
- NTRK translocation: from general to specific
- Genetic profile of patients with stage I–IIIA non-small cell lung cancer
- Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.